
Japan’s Shionogi, creator of the blockbuster cholesterol treatment Crestor, announced on Monday, March 30, it would tie up with Ping An Insurance Group of China, selling a 2.05% voting stake for 33.53 billion yen (US$311 million).
Shionogi will form a joint venture with the Chinese group’s unit, Ping An Life Insurance of China Ltd, with the aim of discovering and distributing new drugs and developing generic ones as it looks to expand in China, reported Reuters.
“To attain our growth strategy beyond 2020, we must realize the expansion of our business in China, which is expected to show the greatest pharmaceutical market growth in the world over the next 10 years,” Shionogi said in the statement.
Shionogi, which gains roughly half its revenue from royalties, posted four-straight years of record operating profit through 2019. It focuses on infectious diseases but a looming patent cliff for its HIV treatments will create an earnings gap that will be hard to completely offset.
Ping An Insurance Group, China’s largest insurer by market value, said in February it expected the coronavirus outbreak to affect its business in the first half.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Elon Musk Leads $97.4 Billion Bid to Take Control of OpenAI
Feb 10, 2025 by
CPI
Nigerian Court Confirms Consumer Protection Commission’s Authority Over Telecom Sector
Feb 10, 2025 by
CPI
Microsoft Under French Antitrust Investigation Over Bing Practices
Feb 10, 2025 by
CPI
Hausfeld Grows Antitrust Litigation Team
Feb 10, 2025 by
CPI
Microsoft Seeks to Ease EU Antitrust Concerns With Office Pricing Adjustment
Feb 10, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon